Late stage pipeline

Focus on Innovation and Science to unlock mid-term potential

Pipeline updated as of March 2023

Molecule / Project
Indication
Expected Launch
Preclinical Phase Phase I Phase II Phase III Under Registration Geography
Efinaconazole Onychomycosis
2024
99 Under registration
EU EU
Sarecycline Acne
2024
95 Under registration
China China
Tribanibulin
LF
Actinic keratosis
EU 2026
75 Fase3
EU EU
ALM223
Early stage
Autoimmune dermatology
TBD
27 Fase1
Worldwide Worldwide *
ALM401 Autoimmune dermatology
TBD
39 Fase1
Worldwide Worldwide
ALM27134 Autoimmune dermatology
TBD
33 Fase1
Worldwide Worldwide

Onychomycosis Efinaconazole 2024 Under registration EU

Acne Sarecycline 2024 Under registration china

Actinic keratosis Tribanibulin
LF EU 2026 Fase3 EU

Autoimmune dermatology ALM223
Early stage TBD Fase1 worldwide_exchina
‏‏* Worldwide ex-Greater China

Autoimmune dermatology ALM401 TBD Fase1 worldwide

Autoimmune dermatology ALM27134 TBD Fase1 worldwide